Biopool International Announces the Appointment of Dr. Denis O. Rodgerson as Clinical Advisor.

VENTURA, Calif.--(BW HealthWire)--Jan. 25, 1999--Biopool International Inc. (Nasdaq:BIPL) Monday announced that Denis O. Rodgerson, Ph.D., will become a clinical advisor to the company effective immediately.

Rodgerson is currently professor emeritus at the University of California, Los Angeles (UCLA). He has held numerous positions and served on many committees at UCLA since 1974. Positions held recently have included professor and vice chairman, Department of Pathology and Laboratory Medicine, and head of clinical chemistry at the School of Medicine.

Committee membership has included System-Wide Legislative Assembly and Information Transfer and Technology. He was instrumental in establishing the very successful Clinical Product Development Program for the Department of Pathology and Laboratory Medicine.

Rodgerson has been an active member of the American Association for Clinical Chemistry since 1964, holding various positions within that organization, which have included serving on the board of directors and as chairman of the National Performance Evaluation Committee.

Rodgerson has also served as a consultant to many prestigious groups and organizations including NASA, the National Bureau of Standards, and the Battelle Research Institute in Columbus, Ohio, and Geneva, Switzerland. He has authored or co-authored more than 145 publications on a vast array of biomedical and clinical laboratory subjects.

"The establishment of this position with such an eminent researcher and scholar as Dr. Rodgerson will strongly support the company's continued efforts as a developer of unique specialty in-vitro diagnostic reagents that address evolving clinical developments, especially in cardiovascular medicine," stated Michael D. Bick, Ph.D., chairman and chief executive officer of Biopool.

"We expect that this will be a precursor to the development of a Clinical Advisory Board that includes people active in specialties that become of clinical interest to better patient care."

Bick continued: "We are indeed excited about working with Dr. Rodgerson in expanding our vision and aiding in the development of additional leadmeaningful new dimension to our business develop risk factors, fibrinolysis, platelet function,d type whole blood.

The company's productding the development of a Clinical Advisory Boa technological innovations of competitors, changes in health-care regulations, litigation claims, foreign currency fluctuation, product acceptance, or changes in government regulation of the company's products, as well as other factors discussed in the company's last report on Form 10-K-SB under "Risk Factors."